SCHOLAR ROCK HOLDING CORPORATION Investment Income, Nonoperating
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Investment Income, Nonoperating of $4.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNonoperating · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION investment income, nonoperating for the quarter ending 2026-06-30 was $4.09M, a 19.99% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION investment income, nonoperating for the quarter ending 2026-03-31 was $2.94M, a 30.60% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION investment income, nonoperating for the quarter ending 2025-12-31 was $3.53M, a 22.69% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION investment income, nonoperating for the quarter ending 2025-09-30 was $2.73M, a 31.20% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION investment income, nonoperating for fiscal 2025 was $13.90M, a 9.60% increase from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION investment income, nonoperating for fiscal 2024 was $12.68M.
| Period end | Investment Income, Nonoperating 3 month | Investment Income, Nonoperating 6 month | Investment Income, Nonoperating 9 month | Investment Income, Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.09M 10-Q · filed 2026-08-06 | $7.03M 10-Q · filed 2026-08-06 | $10.55M derived: sum of 3 quarters · filed 2026-08-06 | $13.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.94M 10-Q · filed 2026-05-07 | $6.46M derived: sum of 2 quarters · filed 2026-05-07 | $9.19M derived: sum of 3 quarters · filed 2026-05-07 | $12.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $6.26M derived: sum of 2 quarters · filed 2026-03-03 | $9.67M derived: sum of 3 quarters · filed 2026-08-06 | $13.90M 10-K · filed 2026-03-03 |
| 2025-09-30 | $2.73M 10-Q · filed 2025-11-14 | $6.14M derived: sum of 2 quarters · filed 2026-08-06 | $10.37M 10-Q · filed 2025-11-14 | $14.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $3.41M 10-Q · filed 2026-08-06 | $7.64M 10-Q · filed 2026-08-06 | $12.20M derived: sum of 3 quarters · filed 2026-08-06 | $14.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.23M 10-Q · filed 2026-05-07 | $8.79M derived: sum of 2 quarters · filed 2026-05-07 | $10.87M derived: sum of 3 quarters · filed 2026-05-07 | $13.59M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $4.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $6.64M derived: sum of 2 quarters · filed 2026-03-03 | $9.36M derived: sum of 3 quarters · filed 2026-03-03 | $12.68M 10-K · filed 2026-03-03 |
| 2024-09-30 | $2.08M 10-Q · filed 2025-11-14 | $4.80M derived: sum of 2 quarters · filed 2025-11-14 | $8.12M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $2.72M 10-Q · filed 2025-08-06 | $6.04M 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |